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Maturation and release of the Ebola virus glycoprotein GP were studied in cells infected with either Ebola or recombinant
vaccinia viruses. Significant amounts of GP were found in the culture medium in nonvirion forms. The major form represented
the large subunit GP1 that was shed after release of its disulfide linkage to the smaller transmembrane subunit GP2. The
minor form were intact GP1,2 complexes incorporated into virosomes. Vector-expressed GP formed spikes morphologically
indistinguishable from spikes on virus particles, indicating that spike assembly is independent of other viral proteins. Analysis
of a truncation mutant revealed an early and almost complete release of GP1,2 molecules, showing that membrane anchoring
is mediated by the carboxy-terminal hydrophobic domain of GP2. We have also compared wild-type virus which requires
transcriptional editing for synthesis of full-length GP with a variant that does not depend on editing. Both viruses released
comparable amounts of GP1, but the variant expressed only minute amounts of the small, soluble GP which is the expression
product of nonedited mRNA species of the GP gene. The abundant shedding of soluble GP1 may play an important role in
the immunopathology of Ebola hemorrhagic fever in experimentally and naturally infected hosts. © 1998 Academic Press
INTRODUCTION
Ebola viruses (EBOV) are among the most severe
human pathogens causing hemorrhagic fever, with mor-
tality rates up to 88%. The recent reemergence of Ebola
in Zaire and Gabon (1994–1997), as well as the introduc-
tion of EBOV-Reston into the United States and Italy by
imported macaques from the Philippines, once again
showed that these viruses have to be considered patho-
gens with public health impact even in nonendemic,
developed countries.
EBOV subtype Zaire is the prototype of the Ebola
species that together with the Marburg species consti-
tute the family Filoviridae (Murphy et al., 1995). Filovirus
particles have a characteristic filamentous form. They
show a uniform diameter of approximately 80 nm, but
vary greatly in length (Geisbert and Jahrling, 1995). Neg-
atively contrasted particles, regardless of serotype or
host cell, contain an electron-dense central axis (19–25
nm in diameter) surrounded by an outer helical layer
(45–50 nm in diameter) with cross-striations at 5-nm
intervals. This central core is formed by the ribonucleo-
protein complex that consists of the nonsegmented neg-
ative-stranded RNA genome and the virion structural
proteins (VP) 30, VP35, nucleoprotein (NP), and polymer-
ase (L) protein. Three other structural proteins (VP40,
glycoprotein (GP), and VP24) are membrane-associated.
Spikes of approximately 7 nm in diameter are formed by
GP oligomers and spaced at about 5- to 10-nm intervals
on the surface (Feldmann and Klenk, 1996; Peters et al.,
1996).
In general, filovirus proteins are encoded in single
reading frames (Feldmann et al., 1992; Sanchez et al.,
1993). The EBOV surface GP, however, is encoded in two
frames (ORF I and II), and expression of GP occurs
through transcriptional editing (Volchkov et al., 1993,
1995; Sanchez et al., 1996). During the intracellular path-
way EBOV GP is extensively N- and O-glycosylated, with
carbohydrates accounting for .50% of the molecular
weight (Feldmann et al., 1994; Volchkov et al., 1995).
Furthermore, maturation of GP involves processing of an
endoplasmatic precursor (preGPer) into an endo H-resis-
tant Golgi-specific precursor (preGP). preGP is subse-
quently cleaved by a subtilisin-like protease, most likely
furin, into the subunits GP1 (140 kDa) and GP2 (26 kDa)
that are linked by a disulfide bond in the mature complex
GP1,2 (Volchkov et al., 1998). Sequence analysis suggests
that EBOV GP is a type I transmembrane glycoprotein
anchored via a hydrophobic domain close to the car-
boxy-terminal end of GP2 (Volchkov et al., 1992, 1993).
The removal of a signal peptide at the amino-terminal
end and oligomerization have to be predicted for EBOV
GP processing, as has been shown earlier for Marburg
virus (Feldmann et al., 1991; Will et al., 1993). ORF I
(amino-terminal) of the GP gene encodes for a small
glycoprotein (sGP) that is expressed from unedited tran-
scripts. sGP is a nonstructural protein of EBOV that is
effectively secreted into culture medium (Volchkov et al.,
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1995; Sanchez et al., 1996). Recently sGP was detected in
blood of acutely infected patients (Sanchez et al., 1996).
The molecular mechanisms involved in surface accu-
mulation of GP1,2 and in its interaction with other viral
proteins in virus assembly and budding are poorly un-
derstood. The data presented here demonstrate that
EBOV GP is not only incorporated into virions, but that a
larger fraction is present as nonvirion molecules. This
nonvirion fraction mainly consists of soluble GP1, but
small quantities of GP1,2 complexes associated with
membrane vesicles are also found. We further show that
vector-expressed GP1,2 forms spikes on virosomes mor-
phologically indistinguishable from those on filovirus
particles, indicating that spike assembly is independent
of the expression of any other viral protein. Similar viro-
somes are also released from EBOV-infected cells.
RESULTS
As shown elsewhere, EBOV GP appears first as an
endoplasmic precursor of 110 kDa (preGPer), and then as
a 160-kDa Golgi-specific precursor (preGP) which sub-
sequently is cleaved into GP1 and GP2. Mature GP (GP1,2)
consists of disulfide-linked GP1 and GP2 (Volchkov et al.,
1998). In this paper we investigated the release of EBOV
GP into culture medium by using a recombinant vaccinia
virus (vSCGP8) or transient expression from the plasmid
pGEM-mGP8 (vTF7-3 system) that both predominantly
express GP without RNA editing (Volchkov et al., 1995).
To also study this process in EBOV-infected cells, two
subtype Zaire viruses were examined, which differed in
the strategy of GP expression. Strain Eckron (EBOV-7U)
was used as wild-type virus expressing GP from approx-
imately 20% of the GP-specific mRNAs that are gener-
ated by transcriptional editing (Volchkov et al., 1995,
1997; Sanchez et al., 1996). EBOV-8U is a plaque-purified
variant of strain Mayinga carrying an insertion of a single
uridine residue at the editing site (Sanchez et al., 1993).
This virus therefore resembles vSCGP8 in the mecha-
nism of GP expression. To investigate the influence of
the transmembrane anchor domain and/or the cytoplas-
mic tail on transport, maturation and release of EBOV GP
we constructed a plasmid expressing an anchor-minus
GP (GPDTm) that was used for transient expression by
the vTF7-3 system.
GP of Ebola virus is released into culture medium
The mature GP1,2 complex consists of the two disul-
fide-linked cleavage products GP1 (140 kDa) and GP2 (26
kDa) (Volchkov et al., 1998). In order to study the kinetics
of GP processing Hela cells infected with vSCGP8 were
pulse-labeled for 20 min with [35S]cysteine and chased
for different time intervals. Cell lysates and medium were
analyzed separately for the presence of GP by quantita-
tive immunoprecipitation using anti-EBOV immunoglobu-
lins (Fig. 1). GP1 was not only found in cells, but also
detected in culture medium. The kinetics of GP1 release
correlated well with the processing of intracellular GP
(Fig. 1A). Following a 20-min pulse GP was first detected
as the endoplasmatic precursor (preGPer) that was con-
verted into the Golgi-specific precursor (preGP) within 30
min of chase [Figs. 1A and 1B (left part)]. The size
difference between preGP and GP1 is more striking if the
tail elongation mutant GPLT is expressed (Fig. 1B, right
part). The number of intracellular cleavage products in-
FIG. 1. Expression of recombinant GP. HeLa cells were infected with
either vSCGP8 or vTF7-3 and subsequently transfected with either
pGEM–mGP8 or pGEM-GPLT. Cells were labeled with [35S]cysteine for
20 min at 4 h p. i. and subsequently chased for various times, as
indicated. Labeled proteins from cell lysates and culture medium were
immunoprecipitated using goat anti-EBOV immunoglobulins (1:100) and
subjected to SDS–PAGE. (A) Pulse–chase analysis (infection with
vSCGP8). Samples of cell lysates (top part) and medium (bottom part)
were run on 10% SDS–PAGE under reducing conditions. (B and C)
Proteolytic processing and release of GP1 (transient expression). Sam-
ples of cell lysates and medium subjected to 8% SDS–PAGE under
reducing conditions (B) and 10% SDS–PAGE under reducing and non-
reducing conditions (C). Key: C, cell lysate; M, culture medium; (2)
nonreducing conditions; GPLT, EBOV GP tail elongation mutant; GP,
wild-type EBOV GP; (1) reducing conditions.
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creased within the first 120 min after synthesis (Fig. 1A).
Over the next 360 min of chase the amount of intracel-
lular GP1 decreased, while extracellular GP1 concomi-
tantly increased. Finally, both remained at constant lev-
els for at least 600 min postsynthesis, and no additional
release occurred thereafter. Quantification (Fuji BAS
1000 Bio-Imaging Analyzer) revealed that the proportion
of intra- and extracellular GP1 changed from 86:14 after
240 min to 24:76 after 10 h of chase. Within the last 360
min postsynthesis the total amount of intracellular and
released GP did not decrease, indicating that significant
degradation or turnover did not take place within this
period (Fig. 1A). SDS–PAGE analysis under reducing and
nonreducing conditions confirmed that the released pro-
tein was predominantly GP1, which could only be distin-
guished from GP1,2 complexes under nonreducing con-
ditions (Fig. 1C).
An anchor-minus mutant (GPDTm) was constructed by
introducing a stop codon at position 651 to investigate
the functional role of the carboxy-terminal hydrophobic
domain. Pulse–chase analysis demonstrated that syn-
thesis and processing of GPDTm was similar to that of
wild type (Fig. 2A), but GPDTm1,2 was released immedi-
ately after maturation (240 min of chase) in contrast to
wild type GP (Figs. 1A and 2A). Immunoblot analysis
confirmed that only molecules with mature carbohy-
drates were secreted (Fig. 2B, lanes 3, 4, 7, 8, 11, and 12),
as has been observed for sGP earlier (Volchkov et al.,
1995). Released and intracellular GP1 of both wild-type
GP and GPDTm were resistant to endo H digestion, but
shifted to a decreased molecular weight after PNGase F
treatment (Fig. 2B), indicating a similar maturation pro-
cess for both molecules. The finding that intracellular
preGPer migrated faster than GP1 even after PNGase F
digestion (Fig. 2B, lane 5) suggested that GP1 contained
additional O-linked oligosaccharides, as described pre-
viously (Feldmann et al., 1994). Expression of GPDTm
resulted mainly in the release of GP1,2 complexes and
only a small number of soluble GP1 and truncated GP2
molecules, as demonstrated under nonreducing SDS–
PAGE conditions (Fig. 2C, left part). This was in contrast
to expression of wild-type GP, where mainly GP1 was
released into culture medium (Fig. 1C) and GP2 remained
membrane-associated (Fig. 2C, right part). These data
illustrated that disulfide linkage occurred prior to proteo-
lytic processing and that the hydrophobic domain indeed
serves as a transmembrane anchor.
Released GP is present in a soluble and a
membrane-associated form
To investigate the physical properties of released GP,
culture medium of cells expressing recombinant GP was
subjected to sucrose equilibrium gradient analysis and
detergent solubility studies (Fig. 3). Released GP was
detected on top of the 10–40% sucrose density gradient
FIG. 2. Expression of anchor-minus GP (GPDTm). HeLa cell mono-
layers were infected with the recombinant vaccinia virus vTF7-3
followed by transfection with pGEM-mGP8 or pGEM-GPDTm. (A)
Pulse–chase analysis of GPDTm. Four hours posttransfection cells
were labeled with [35S]cysteine for 20 min and subsequently chased
for various times as indicated. Labeled proteins from cell lysates
and culture medium were immunoprecipitated using goat anti-EBOV
immunoglobulins (1:100) and subjected to 10% SDS–PAGE. (B) En-
doglycosidase digestion of GP and GPDTm. Proteins from cell ly-
sates (C ) and culture medium (M) were treated with endo H or
PNGase F and subsequently separated on 10% SDS–PAGE and
blotted onto PVDF membranes. Two forms of GP (GP1 and preGPer)
were detected intracellularly by immunoblotting using goat anti-
EBOV immunoglobulins (1:3000). Only GP1 was released into culture
medium. Lanes 1, 5, and 9—lysates of cells transfected with pGEM-
mGP8; lanes 2, 6, and 10—medium of cells transfected with pGEM-
mGP8; lanes 3, 7, and 11—medium of cells transfected with pGEM-
GPDTm; lanes 4, 8, and 12—lysates of cells transfected with pGEM-
GPDTm. The positions of preGPer and GP1 before and after*
endoglycosidase treatment (PNGase F, endo H) are indicated. (C)
Immunoprecipitation of GP and GPDTm from culture medium. La-
beling was performed at 4 h posttransfection with [35S]cysteine for
20 min. Subsequently, cells were chased for 240 min. Culture me-
dium was immunoprecipitated with goat anti-Ebola immunoglobu-
lins and precipitated proteins were subjected to 10% SDS–PAGE
under nonreducing (left part) and reducing (right part) conditions.
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(fractions 6–10) as well as in gradient fractions 1 to 3 at
sucrose concentrations of approximately 30–35% (Fig.
3A). Quantitative analysis with the Fuji BAS 1000 Bio-
Imaging Analyzer (Raytest, Germany) showed that the
ratio between moderately and quickly sedimenting GP
was approximately 10:1 (Fig. 3). Slowly sedimenting GP
(fractions 6–10) represented soluble GP1, as determined
by comparison under reducing and nonreducing SDS–
PAGE conditions, whereas fractions 1–3 contained GP1,2
complexes (Fig. 3A). These complexes could be detected
several hours postsynthesis and not at early stages, as
shown in Fig. 1. Due to editing properties of T7 RNA
polymerase (Volchkov et al., 1995) sGP was detected in
fractions containing slowly sedimenting GP. Flotation
analysis on a 10–40% sucrose gradient revealed that the
main part of the released GP stayed on the bottom of the
gradient (GP1), whereas a minor fraction floated into the
gradient (Fig. 3B, left part). When culture medium was
subjected to flotation analysis on a sucrose gradient
containing 0.1% Triton X-100, released GP totally re-
mained on the bottom of the gradient (Fig. 3B, right part).
All these results indicate that GP is released into culture
medium in two forms: as soluble GP1 (major fraction) and
as membrane-bound nonvirion GP1,2 complexes.
GP and sGP are released during EBOV infection
In order to also investigate the release of EBOV GP
during virus replication Vero-E6 cells were infected with
two subtype Zaire viruses (EBOV-7U and EBOV-8U) that
differed in their strategy of GP expression (see above).
Culture medium was subjected to sucrose equilibrium
centrifugation and analyzed for the presence of viral
glycoproteins by SDS–PAGE and immunoblot analysis
using goat anti-EBOV immunoglobulins (Fig. 4A). With
both viruses synthesis and release of GP was compara-
ble. Similar to recombinant GP, significant amounts (ap-
proximately 50%) of GP were released into the culture
medium in a soluble form (GP1) (Fig. 4A, fractions 8 to
10). Other virion structural proteins were found mainly in
the gradient fractions containing intact virus particles
(Fig. 4, fractions 1 to 3) or prior to ultracentrifugation of
culture medium (Fig. 4B), indicating a specific release
mechanism rather than cytolysis for the appearance of
extracellular GP1 during EBOV infection. As shown in Fig.
FIG. 3. Centrifugation analysis of medium obtained following recombinant expression of GP. HeLa cells were infected with vTF7-3 at an m.o.i. of
10 and transfected with pGEM-mGP8. Culture media of [35S]cysteine-labeled or unlabeled cultures were clarified by low-speed centrifugation. (A)
Sucrose equilibrium gradient analysis of labeled material. An aliquot of the medium was loaded onto a linear sucrose gradient (10 to 40%, w/w) and
12 fractions (1 ml) were collected from the bottom to the top following centrifugation at 36,000 rpm and 4°C for 20 h in a SW 41 rotor (Beckman).
Samples were immunoprecipitated by goat anti-EBOV immunoglobulins prior to subjection to 10% SDS–PAGE under reducing (left part) or 8%
SDS–PAGE under nonreducing conditions (right part). The numbers indicate the gradient fractions which are loaded on the gel from the bottom to
the top. (B) Flotation analysis of unlabeled material. Aliquots of the medium were mixed with sucrose (final concentration of 50%) in the absence (left
part) or the presence (right part) of Triton X-100 (1 mg/ml). Subsequently, samples were laid under a linear sucrose gradient (10–40%, w/w) with or
without Triton X-100 (1 mg/ml) and subjected to centrifugation at 40,000 rpm and 4°C for 20 h in a SW60 rotor (Beckman). A total of 11 fractions (0.4
ml) were collected and detection of EBOV proteins was performed by immunoblotting using goat anti-EBOV immunoglobulins (1:3,000 dilution). The
numbers indicate the gradient fractions which are loaded on the gel from the bottom to the top. Note, membrane-associated GP (GP1,2) appears as
GP1 under reducing conditions (see designation).
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4A, EBOV-7U and EBOV-8U drastically differed in the
amount of sGP expression. Whereas infection with
EBOV-7U led to a very efficient expression and release of
sGP, only trace amounts of sGP were synthesized and
secreted during EBOV-8U infection (Fig. 4A).
Vector expressed GP forms spikes
Membrane-associated GP isolated by flotation analy-
sis from culture medium of vSCGP8-infected cells (Fig.
3B) was examined by electron microscopy after negative
staining with potassium phosphotungstate. In fractions
containing floated GP (Fig. 3B, left part; lanes 7 and 8)
virosomes were detected. These particles varied in form
and diameter, but showed uniform spike structures on
their surfaces (Figs. 5A–5C). The spikes could not be
distinguished morphologically from those on character-
istic filamentous EBOV particles, as shown in Fig. 5F.
Immunogold labeling with goat anti-EBOV immunoglobu-
lins confirmed that the spikes on these particles ob-
tained after vSCGP8 infection were formed by GP (Figs.
5D and 5E). This result clearly demonstrated that vector-
expressed GP formed spikes on membrane surfaces and
that no other viral proteins were needed in this matura-
tion process. Similar vesicles were also found during
EBOV infection (Fig. 5G), when gradient fractions with
lower densities (Fig. 4A, fractions 3 and 4) were com-
pared with fractions containing virus particles (Fig. 4,
fractions 1 to 3).
DISCUSSION
The release of structural proteins in nonvirion form has
been observed before with other viruses, and the follow-
ing different mechanisms have been described: (i) Re-
lease as a result of cell lysis during viral infection. This
has been demonstrated for soluble VSV proteins that
account for about 3% of total viral proteins in an infected
culture (Kang and Prevec, 1971; Little and Huang, 1978).
(ii) Release of viral structural glycoproteins as a result of
proteolytic cleavage by cellular proteases. This has been
demonstrated for the soluble G protein of VSV (Irving and
Gosh, 1982; Chen and Huang, 1986) and rabies virus
(Dietzschold et al., 1983; Morimoto et al., 1993), soluble
HA of measles virus (Malvoisin and Wild, 1994), soluble
G protein of RSV (Hendricks et al., 1987), HA1 subunit of
influenza A hemagglutinin (HA) (Roberts et al., 1993), and
GP120 of HIV (Veronese et al., 1985). (iii) Budding of
virus-like particles with incorporated viral proteins. This
has been described for surface antigen of the hepatitis B
virus (Moriarty et al., 1981), the E proteins of a number of
flaviviruses (Mason et al., 1991; Yamshchikov and Com-
pans, 1993; Allison et al., 1995), envelope proteins of
lentiviruses (Kra¨usslich et al., 1993; Yamshchikov et al.,
1995), the small envelope protein (E) of coronavirus (Ven-
nema et al., 1996), and for recombinant VSV G protein
expressed using the Semliki Forest virus (SFV) system
(Rolls et al., 1994, 1996). In addition, viral glycoproteins
are also released after removal of the transmembrane
anchor region by genetic engineering. This has been
shown for rubella virus glycoprotein (Seto et al., 1995),
influenza virus hemagglutinin (Gething and Sambrook,
1982), and VSV glycoprotein G (Rose and Bergmann,
1982).
After infection with EBOV-7U and EBOV-8U, mature
GP1,2 was incorporated into virus particles, and GP1 was
FIG. 4. Release of nonvirion glycoproteins from EBOV-infected cells.
Vero-E6 cells were infected with EBOV-7U and EBOV-8U with an m.o.i.
of 1022. Culture medium was harvested 5 days postinfection. (A) Su-
crose equilibrium gradient analysis of culture medium obtained follow-
ing infection with EBOV-7U (top part) and EBOV-8U (bottom part).
Aliquots of the culture media were separated on linear sucrose gradi-
ents (10 to 40%, w/w) and 12 fractions (1 ml) were collected from the
bottom to the top of the gradient following centrifugation at 36,000 rpm
and 4°C for 20 h in a SW41 rotor (Beckman). Proteins were analyzed
following 10% SDS–PAGE by immunoblotting using goat anti-EBOV
immunoglobulins (1:3000). The numbers indicate the gradient fractions
which are loaded on the gel from the bottom to the top. (B) Analysis of
culture medium prior to or after clearance of viral particles by ultracen-
trifugation. Ultracentrifugation was performed in a Beckman SW28 rotor
at 20,000 rpm for 2 h at 4°C. Proteins were subjected to 10% SDS–PAGE
under reducing conditions and blotted onto PVDF membranes, and
viral proteins were detected with goat anti-Ebola immunoglobulins
(1:3000). Lane, 1, culture medium of EBOV-7U-infected cells; lane 2,
culture medium of EBOV-7U-infected cells after ultracentrifugation.
Note. two times the material was applied in lane 2).
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extensively released in a soluble, nonvirion form (Fig. 4).
The observation that other viral proteins were not
present in the medium in soluble form indicated that the
release of GP1 was not due to destruction of infected
cells or viral particles. The extracellular appearance of
GP1 was also demonstrated in cells expressing recom-
binant GP (Figs. 1–3). As indicated by the earliest ap-
pearance of GP1 in the culture medium, GP processing
and transport took approximately 90–120 min (Fig. 1A).
Similar maturation kinetics have been observed with
several other viral glycoproteins (Doms et al., 1993).
Expression of an anchor-minus mutant of EBOV GP (Fig.
2) showed a processing pathway similar to that observed
with wild-type GP, but an earlier and almost complete re-
lease of soluble disulfide-linked GP1,2 molecules in contrast
to soluble GP1 for wild type. These data indicate that (1) the
proposed carboxy-terminal hydrophobic domain functions
as the membrane anchor of GP, although additional hydro-
phobic domains are present on the molecule (Volchkov et
al., 1992), and (2) essential signals for processing and
transport are not located in the transmembrane anchor and
cytoplasmic domain of GP.
FIG. 5. Electron micrographs of virosomes. Different fractions of the sucrose equilibrium gradient or flotation analyses of EBOV-7U- or vSCGP8-
infected cells were analyzed by electron microscopy after potassium phosphotungstate staining. For immunogold staining fractions were treated with
goat anti-EBOV immunoglobulins (1:100) followed by a rabbit anti-goat serum conjugated with gold particles (10 nm) prior to potassium phospho-
tungstate staining. Spike structures on virosomes and virus particles are indicated by black arrowheads. (A to C) Fractions containing virosomes
(vSCGP8 infection). Bar in A, 80 nm; B and C are identical in magnification with A. (D and E) Immunogold staining of virosomes (vSCGP8 infection).
Bar in D, 50 nm; E is identical in magnification with D. (F and G) Fractions containing EBOV particles and virosomes, respectively (EBOV-7U infection).
Bar in F, 170 nm; bar in G, 80 nm.
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Our data show that GP1 is released from the complex
with GP2 during processing (Fig. 1). A similar mechanism
had been postulated for the shedding of the HA1 subunit
of the influenza HA (Roberts et al., 1993) and of GP120 of
HIV (Veronese et al., 1985). Since GP120 and GP41 of HIV
are not linked by disulfide bonds, release of GP120 may
occur spontaneously. In the case of influenza virus an
acid-induced conformational change of the cleaved HA
in the trans-Golgi network and/or in transport vesicles
destined for the plasma membrane may make the disul-
fide linkage between HA1 and HA2 susceptible to reduc-
tion (Roberts et al., 1993). Since GP1,2 also contains a
disulfide linkage that is formed prior to proteolytic cleav-
age, as demonstrated by the analysis of the anchor-
minus mutant (Fig. 2), such a mechanism is also sug-
gested for the release of GP1. As an alternative mecha-
nism, disulfide linkage may not be always completed
between the GP1 and GP2 domains of preGPer during
early processing of GP. Thus, proteolytic processing in
the Golgi of these molecules would lead to a release of
GP1 molecules.
A minor fraction of nonvirion GP (GP1,2) was mem-
brane-associated and released as spikes on virosomes
(Fig. 5). The spikes of these vesicles were morphologi-
cally indistinguishable from virion spikes and vesicles
appeared either after vector expression of GP or after
virus infection (Fig. 5). We cannot exclude the possibility
that virosomes result from a cytopathic effect caused by
EBOV or vaccinia viruses in culture rather than a specific
mechanism triggered by GP expression. Morphological
studies on EBOV-infected animals, however, demon-
strated areas of cellular membrane proliferation. These
areas seemed not to be directly involved in virus budding
(Riabchikova et al., 1993; Geisbert and Jahrling, 1995),
and further studies have to clarify if they could be asso-
ciated with a specific release of virosomes. The biolog-
ical function of released nonvirion membrane-associated
GP is unknown and may be irrelevant due to limited
quantities. However, the release of virosomes from
plasma membranes of vSCGP8-infected cells clearly
demonstrated that spike formation is mediated by GP
expression alone and independent of the expression of
other viral proteins.
The abundant release of GP1 and secretion of sGP
suggest biological functions which have not yet been
determined. During filovirus infection in humans and
animals lymphoid depletion and necrosis of lymphoid
tissue including destruction of noninfected macrophages
and other antigen-presenting cells (APCs) have been
described. Furthermore, a lack of cellular immune re-
sponse against virus-infected cells has been reported
(Ryabchikova et al., 1996; Zaki and Peters, 1997). These
observations may implicate that macrophages or other
APCs are lysed by CD41-bearing T-cells after presenting
processed GP1 and sGP in context with MHC class II
antigens. The destruction of these cells might be respon-
sible for the insufficient cellular and humoral immune
responses observed in the course of EBOV infection.
This concept is supported by the observations that un-
infected cells exposing processed soluble viral glyco-
proteins of HIV (Siliciano et al., 1988), VSV (Browning et
al., 1990), and influenza virus (Morrison et al., 1986, 1988)
are efficiently lysed by virus-specific CD41 T-lympho-
cytes (MHC class II-restricted). Class II MHC antigen is
mainly expressed on the surface of professional APCs
including B lymphocytes and can also be found after
activation on other cells, such as endothelial cells. The
lysis of GP1- and sGP-exposed endothelial cells by
CD41-bearing T-cells may in addition to destruction by
virus replication (Schnittler et al., 1993) further contribute
to the bleeding symptoms observed in patients. Re-
leased GP1 and secreted sGP may also interfere with
humoral defense mechanisms. Specific antibodies may
bind to these molecules and therefore be no longer
available for virus elimination.
If nonvirion glycoproteins are determinants of viral
pathogenicity during EBOV infection, this role seems to
be more related to shedding of GP1 than to sGP secre-
tion. This is supported by the following observations: (i)
EBOV-7U (wild type) and EBOV-8U (variant) that display
high pathogenicity in animal models, such as guinea
pigs and monkeys (Chepurnov et al., 1995; Ryabchikova
et al., 1996), produce comparable amounts of released
GP1, but EBOV-8U expresses only minute amounts of
sGP (Fig. 4). (ii) Subtype Reston EBOV produces high
levels of sGP (Sanchez et al., 1996), but is less patho-
genic for man and some monkeys than the African EBOV
subtypes (Peters et al., 1994; Fisher-Hoch et al., 1992).
(iii) Marburg hemorrhagic fever is a comparable disease
in human and nonhuman primates, but there is no evi-
dence for sGP expression during infections with Mar-
burg virus (Will et al., 1993; Bukreyev et al., 1995; Feld-
mann and Klenk, 1996; Becker et al., 1996).
Finally, released GP1 and sGP may interfere with cel-
lular receptors and, therefore, reduce the efficiency of
Ebola virus replication. This does not seem to hold true
for infections in humans and experimental animals, but
may play a role in establishing a persistent infection in
the yet unknown natural host.
MATERIALS AND METHODS
History and propagation of viruses
The EBOV strain Eckron, subtype Zaire, was received
from the Institute Voor Tropische Geeneskunde, Ant-
werp, Belgium. This virus strain, as EBOV strain Mayinga,
was isolated from a case of the 1976 outbreak of Ebola
hemorrhagic fever in Zaire (S. R. Pattyn, personal com-
munication) and represents a wild-type strain (EBOV-7U)
with an editing site of seven consecutive uridine resi-
dues (GenBank Accession No. U81161; Volchkov et al.,
1997). The EBOV strain Mayinga, subtype Zaire, was
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received from the Special Pathogens Branch, Centers for
Disease Control and Prevention (Atlanta, GA). This virus
represents a variant with eight consecutive uridine res-
idues at the editing site (EBOV-8U) (Sanchez et al., 1993,
1996). EBOV were cultured in Vero cells, clone E6 (ATCC
CRL 1586), as described earlier (Feldmann et al., 1991).
The recombinant vaccinia virus expressing the bacterio-
phage T7 RNA polymerase (vTF7-3) was kindly provided
by B. Moss, National Institute of Health (Bethesda, MD)
and propagated in Vero-E6 cells. The recombinant vac-
cinia virus expressing the EBOV GP (vSCGP8) (Volchkov
et al., 1995) was propagated on CV-1 cells. Vero-E6, CV-1,
and HeLa cells were maintained in Dulbecco’s medium
containing 10% fetal calf serum (FCS) (GIBCO, Germany).
Expression of recombinant GP
Construction of the recombinant vaccinia virus express-
ing EBOV GP (vSCGP8) was described previously (Volchkov
et al., 1995). This construct contains eight consecutive uri-
dine residues at the editing site (genomic RNA sense) and
thus expresses full-length virion GP from a single large
ORF. The anchor-minus mutant of GP (GPDTm) was made
by introduction of a point mutation into the native GP se-
quence of the plasmid pGEM-mGP8 (Volchkov et al., 1995)
using a PCR technique and four synthetic oligonucleotides.
Briefly, in a first round of PCR two overlapping GP fragments
were synthesized using N1/N2 and N3/N4 pairs of oligo-
nucleotides [N1 (59-GAAGGATCCTGTGGGGCAACAACA-
CAATG; mRNA sense, nucleotides 114 to 142) and N2
(59-GCCGGTATCTATTGTCTCCATCCTGTC; complementary
to nucleotides 2099 to 2073 mRNA sense), N3 (59-GACAG-
GATGGAGACAATAGATACCGGC; mRNA sense, nucleo-
tides 2073 to 2099), and N4 (59-AAAAAGCTTCTTTCCCTT-
GTCACTAAA, complementary to nucleotides 2492 to 2466
mRNA sense); numbering according to the EBOV GP gene
sequence, GenBank Accession No. U31033]. Oligonucleo-
tides N2 and N3 were complementary to each other in their
sequences and carried mutations (TGG to TAG, underlined)
resulting in a stop codon of the ORF at a position that
encoded the amino-terminal end of the proposed trans-
membrane anchor (position 651). In a second step, full-
length mutated GP was synthesized via PCR using oligo-
nucleotides N1 and N4 on a mixture of the previously
amplified DNA fragments. First- and second-step PCR were
performed using the Expand High-Fidelity System (Boehr-
inger Mannheim, Germany). Oligonucleotides N1 and N4
were synthesized with 59-terminal BamHI and HindIII sites,
respectively, to facilitate cloning into the plasmid vector
pGEM3Zf. The plasmid pGEM-GPLT is a derivative of plas-
mid pGEM-mGP8 (Volchkov et al., 1995) with an insertion of
a single nucleotide at the stop codon leading to a frameshift
and thus expression of a GP tail elongation mutant (GPLT)
with 36 additional amino acids at the carboxy-terminal end.
All mutated clones were verified by sequence analysis
using a cycle sequencing technique based on the dideoxy
chain-termination method.
For transient expression of GP, GPDTm, and GPLT, 1 3
106 HeLa cells were infected with vTF7-3 at a m.o.i. of 10
PFU/cell. One hour postinfection (p. i.), the inoculum was
replaced by the transfection medium containing 3 mg
recombinant plasmids and 5 ml lipofectin (BRL, Germa-
ny). At 16–20 h posttransfection, medium and cells were
harvested separately and analyzed for the presence of
GP. To analyze comparable amounts of intracellular and
released GP, medium was concentrated 10 times using
Centricon-50/Centriprep-50 according to the instructions
of the supplier (Amicon Inc., U.S.A.).
Pulse–chase experiments and immunoprecipitation
HeLa cells (3 3 106) were infected with either vSCGP8
or vTF7-3 (transient expression) at a m.o.i. of 10 PFU/cell.
For transient expresssion, the inoculum was replaced
after 1 h by transfection medium containing recombinant
plasmid DNA (3 mg; 5 ml lipofectin (BRL). Cells were
washed 4 h p. i., starved in methionine/cysteine-free
medium for 1 h, and labeled with 100 mCi/ml [35S]cys-
teine (Amersham, Germany). Following a pulse of 20 min,
medium was replaced by medium containing an excess
of unlabeled cysteine (chase). Cells were treated with
lysis buffer (1% Nonidet P-40, 0.4% sodium deoxycholate,
0.5% BSA, 5 mM EDTA, 100 mM NaCl, 20 mM Tris–HCl,
pH 7.6, 25 mM iodacetamide, 1 mM PMSF) at 4°C and
culture medium was collected separately. To minimize
nonspecific precipitations cell lysate and medium sam-
ples were cleared by centrifugation at 4°C for 15 min at
14,000 rpm in an Eppendorf centrifuge and subsequently
preadsorbed with 50 ml of a 50% (vol/vol) suspension of
protein A–Sepharose (Sigma, Germany) in lysis buffer for
1 h at 4°C, followed by centrifugation as indicated above.
Following preadsorption on HeLa cells for 1 h at 4°C,
goat anti-EBOV immunoglobulins were incubated over-
night at 4°C with the resulting supernatants. A rabbit
anti-goat secondary antibody coupled to protein
A–Sepharose was added to precipitate the immune com-
plexes. The precipitates were washed three times with
lysis buffer and TNE (1:1) and subsequently incubated in
buffer containing 2% SDS for 10 min at 37°C. Prior to
loading onto 8, 10, or 12% polyacrylamide gels (SDS–
PAGE) samples were boiled with or without 5% b-mer-
captoethanol. Precipitated proteins were visualized by
fluorography or quantified with the Fuji BAS 1000 Bio-
Imaging Analyzer (Raytest, Germany).
Sucrose equilibrium gradient and flotation analyses
of proteins
Vero E6 cells were infected with EBOV at 1022 PFU/cell
for 1 h and culture medium was collected 5 days postin-
fection. HeLa cells were infected with vTF7-3 and subse-
quently transfected with plasmid DNA as described under
117RELEASE OF EBOLA VIRUS GLYCOPROTEINS
‘‘Pulse–chase experiments and immunoprecipitation,’’ and
culture medium was collected 10 h postlabeling. Cell cul-
ture medium was clarified by low-speed centrifugation
(1500 g, 10 min 4°C). A fraction of 6 ml was subjected to
centrifugation (Beckmann SW41 rotor, 20 h, 36,000 rpm,
4°C) through a linear 10–40% (w/w) sucrose gradient pre-
pared with PBS buffer. Subsequently, factions of 1 ml were
collected from the bottom of the gradient and analyzed for
the presence of EBOV proteins using an immunoprecipita-
tion technique. For flotation analysis, HeLa cells were in-
fected with vSCGP8 at a m.o.i. of 10 PFU/cell and culture
medium was collected 20 h postinfection. Sucrose was
added to cell culture medium at a final concentration of 50%
(w/w), and half of the sample was treated with Triton X-100
(1 mg/ml). Aliquots (1 ml) of each portion were laid under a
linear 10–40% sucrose gradient prepared in PBS buffer
containing or lacking Triton X-100 (1 mg/ml) and subjected
to centrifugation (Beckmann SW60 rotor, 20 h, 40,000 rpm,
4°C). Fractions (0.4 ml) were collected and EBOV proteins
were detected by immunoblotting.
Electron microscopy and immune electron
microscopy
Aliquots of different fractions of the sucrose equilib-
rium gradient or flotation analyses (vSCGP8-infected
HeLa cells; EBOV-infected Vero-E6 cells) were fixed with
PBS-buffered glutaraldehyde (1%) and paraformaldehyde
(2%) for 30 min. For negative staining, samples were
adsorbed to Formvar-coated nickel grids, stained with
4% potassium phosphotungstate and examined with an
EM 109 (Zeiss) electron microscope. For immune elec-
tron microscopy, samples were adsorbed to Formvar-
coated nickel grids and floated onto a solution of PBS
containing 1% bovine serum albumin and 0.05% Tween
20 (PBST). Grids were treated with goat anti-EBOV im-
munoglobulins (1:100 in PBST). Controls were treated
with the appropriate preserum at the same dilution. The
grids were rinsed six times in PBS and floated onto a
1:50 solution of rabbit anti-goat antibody conjugated with
5-nm gold particles (Sigma, U.S.A.). After washing, sam-
ples were fixed for 2 min in 1% glutaraldehyde and
negatively stained with 2% potassium phosphotungstate.
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